Novilytic: A Year in Review!

2021 was exhilarating and fast-paced. Novilytic is blessed to have a hard-working and intelligent team that challenges each other and traditional norms in chemistry. As a result, we’ve developed groundbreaking technology and have grown our company and its commercialization potential by leaps and bounds. We’re immensely thankful for this talented team!

Here is a review and some goals for 2022:

Company Growth

• Our company went from 3 to 11 employees in 2021. Among the skill sets hired include analytical chemistry, finance, marketing, business development, customer service, and administration. We’ll add more strategic roles in 2022 as commercialization begins!

R&D Product Updates

We made a slight pivot, per multiple customer inputs, to focus entirely on the development of Proteometer modules. This move will ensure faster adoption of the instrument, associated reagents, and analytical columns. We are proud to say the first Beta prototype of this Proteometer module is in pilot testing now! In case you missed it, the Proteometer is an instrument for biopharmaceutical manufacturers who would benefit from enhanced process analytical technology (“PAT”) for monoclonal antibodies. It is the world’s first system capable of testing antibody quality in-process.

• We’ve applied for 2 new patents in 2021 regarding our Proteometer and columns. We are completing two more patent applications currently in our continual effort to increase our already significant strategic advantage. Moreover, a favorable PCT application search report has confirmed the Proteometer's novelty and value.
  

• Our Green Chemistry results prove that our new consumables match market gold standards. These columns will be available for purchase in 2022. Green chemistry is the passion of our own, Dr. Nadine Njoya-Honn, and it focuses on using water and other non-hazardous materials to make chemistry safer for the environment, expectant mothers, and those who are immuno-compromised.
  

• New testing on the patented MASC technology (Mobile Affinity Sorbent Chromatography) is peaking customer interest for “defect detection.”

Corporate Branding and Documentation

• Key messaging and design updates have been implemented on the Novilytic website as well as our sister company, Telimmune’s, website. This is an ongoing project. Be on the lookout for further positive changes to the Novilytic website. Sell sheets and sales materials also developed.
  

• QC and regulatory documentation has been established.

Biz Dev and Partnerships

• We obtained membership with the National Institute of Innovation in Manufacturing Biopharmaceuticals (NIIMBL). This includes a presence at their annual meetings, project proposals, and strategic partnerships with Big Pharma.
  

• We reached a Technology Development Agreement with one of the top 5 U.S.-based CDMO’s (Contract Research and Development Organizations)
  

• Continued work with numerous strategic partners who will assist us with pilot programs and the eventual commercialization of the Proteometer and associated modules.
  

• We’ve signed a master service agreement with Purdue University, providing time and cost savings on projects run through their labs
  

• We also moved our industry-leading plasma collection / separation cards to our sister company, Telimmune.
  

Awards and Events

• We were nominated for and earned 11th position in BestStartups.us' Top 101 bioscience startups list
  

• Our Proteometer technology was presented at NIIMBL’s annual meeting. Our booth and show presence led to our nomination for two NIH Big Pharma programs.
  

• Top 12 finish in Venture Club of Indiana’s Innovation 100 Company Showcase pitch event.
  

• Presented in a "Startup Showcase" event at the University of Notre Dame and shared the vision for the Proteometer with 100+ attendees.

Final Words & 2022 Preview

The year 2022 will be instrumental in the growth of our organization. To that end, we have established the following major goals for the next 12 months:

• Complete the major CDMO technology assessment before the end of Q2
  

• Receive a minimum of one to two on NIIMBL grants valued at $750,000 or more by the end of Q3
  

• Complete a minimum of five successful Proteometer pilots leading towards a sale by the end of Q3
  

• Launch the first consumables for the MASC applications at the start of Q4
  

• Fundraise and gain product approval for three Proteometer modules by the end of Q4

Thank you for being a part of our journey! We look forward to providing periodic updates on our growth and milestones throughout 2022.

Paul C. Dreier. Chief Executive Officer